AdvisorNet Financial, Inc - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.

Quarter-by-quarter ownership
AdvisorNet Financial, Inc ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q2 2023$69,195
+15.0%
1,5000.0%0.01%0.0%
Q1 2023$60,150
-13.4%
1,5000.0%0.01%
-14.3%
Q4 2022$69,495
+12.1%
1,5000.0%0.01%
+16.7%
Q3 2022$62,000
-30.3%
1,5000.0%0.01%
-33.3%
Q2 2022$89,000
-18.3%
1,5000.0%0.01%
+28.6%
Q1 2022$109,000
-13.5%
1,5000.0%0.01%
-12.5%
Q4 2021$126,000
-6.7%
1,5000.0%0.01%
-11.1%
Q3 2021$135,000
-5.6%
1,5000.0%0.01%0.0%
Q2 2021$143,000
-16.4%
1,5000.0%0.01%
-25.0%
Q1 2021$171,000
-17.8%
1,5000.0%0.01%
-29.4%
Q4 2020$208,000
+69.1%
1,5000.0%0.02%
+54.5%
Q3 2020$123,000
+5.1%
1,5000.0%0.01%
+22.2%
Q2 2020$117,000
+74.6%
1,5000.0%0.01%
+50.0%
Q1 2020$67,000
+4.7%
1,5000.0%0.01%
+20.0%
Q4 2019$64,000
-47.5%
1,500
-47.4%
0.01%
-54.5%
Q3 2019$122,000
-32.6%
2,8500.0%0.01%
-45.0%
Q2 2019$181,000
-8.6%
2,8500.0%0.02%
-16.7%
Q1 2019$198,000
+59.7%
2,8500.0%0.02%
+41.2%
Q4 2018$124,000
-26.2%
2,850
+29.5%
0.02%
-19.0%
Q3 2018$168,000
-0.6%
2,2000.0%0.02%
-8.7%
Q2 2018$169,000
+50.9%
2,2000.0%0.02%
+53.3%
Q1 2018$112,000
+9.8%
2,2000.0%0.02%0.0%
Q4 2017$102,0002,2000.02%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2020
NameSharesValueWeighting ↓
EcoR1 Capital, LLC 519,119$40,605,0003.00%
First Light Asset Management, LLC 236,958$18,535,0002.16%
SECTOR GAMMA AS 108,734$8,505,0001.76%
Rock Springs Capital Management LP 646,841$50,596,0001.39%
Atika Capital Management LLC 79,000$6,180,0000.80%
Capital Impact Advisors, LLC 30,582$2,392,0000.80%
FEDERATED HERMES, INC. 4,080,359$319,166,0000.79%
Rhenman & Partners Asset Management AB 61,500$4,811,0000.52%
Ikarian Capital, LLC 73,500$5,749,0000.46%
Capital International, Inc./CA/ 477,858$37,378,0000.46%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders